


Sirion Therapeutics Corporate Fact Sheet

Corporate Profile

Sirion Therapeutics is a privately held, ophthalmic biopharmaceutical company focused on the development and commercialization of innovative advancements for the protection and preservation of eyesight. Sirion has amassed a diverse portfolio of novel products in both early and late stages of development, which address unmet medical needs and offer clear advantages over existing therapies.

Sirion was founded in 2005 with headquarters in Tampa, Florida. The corporate office is comprised of clinical operations, regulatory affairs, pharmacovigilance, and medical affairs departments, as well as commercialization, medical communications, and manufacturing groups. Additionally, Sirion has a state-of-the-art research and development facility located in San Diego, California focused mainly on the development of early stage therapeutics.

Sirion's product pipeline consists of therapies in development for the treatment of uveitis, herpetic keratitis, dry eye syndrome, ocular allergy, and geographic atrophy associated with dry age-related macular degeneration.



* These products are currently in development by Sirion Therapeutics and are not FDA approved.

Sirion continues to diversify its product portfolio with preclinical research and discovery programs focused on front of the eye diseases, as well as innovative cures for retinal diseases. These programs are supported by ongoing work at Sirion's R&D facility and through partnerships with outside collaborators.

Growth Strategy

The goal of Sirion Therapeutics is to be a leading ophthalmic biopharmaceutical company. Sirion's near-term strategy is to complete development and commercialization of existing late-stage product candidates, which are focused on known disease states and have clear marketable advantages. Future strategy includes leveraging the management team's extensive industry expertise, a combined 150 years, to identify and license ophthalmic product opportunities with 'blockbuster' potential. Sirion aims to complement these opportunities with compounds developed internally at the R&D facility.

Product Profiles

Durezol™

Durezol™ (difluprednate ophthalmic emulsion) 0.05% is a topical ophthalmic corticosteroid approved for the treatment of inflammation and pain associated with ocular surgery. In two Phase 3 trials, Durezol rapidly reduced inflammation and pain compared to placebo in patients with significant postoperative inflammation. The approval of Durezol came after a six month priority review by the FDA. Durezol is currently being studied in other ocular inflammatory diseases and conditions. Sirion Therapeutics licensed exclusive worldwide rights, (except Asia) for Durezol from Senju Pharmaceuticals of Japan. For full prescribing information, visit www.durezol.com

Ganciclovir*

Ganciclovir ophthalmic gel 0.15% is a topical ophthalmic antiviral that has been available in Europe as Virgan® for more than a decade and is used to treat herpetic keratitis. In March 2007, ganciclovir ophthalmic gel 0.15% received orphan drug designation from the FDA. Sirion Therapeutics licensed exclusive US rights for ganciclovir ophthalmic gel 0.15% from Laboratories Thea of France.

Cyclosporine*

Cyclosporine ophthalmic solution 0.1% is a topical ophthalmic immunomodulator and immunosuppressive agent intended for the treatment of ocular surface diseases, including dry eye syndrome. Sirion Therapeutics licensed exclusive worldwide rights (except Latin America) for this unique cyclosporine formulation from Laboratorios Sophia of Mexico and it is currently being developed in a Phase 3 program.

Fenretinide*

Fenretinide is an oral vitamin A binding protein antagonist being studied in patients with geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD). Based on preclinical evidence, fenretinide is believed to halt the accumulation of retinol (vitamin A) toxins through its unique affinity for retinol binding protein, a carrier essential for the transport of retinol into photoreceptors. This slows the formation of accumulation of toxic byproducts in the eye, thought to be responsible for vision loss in diseases such as GA and Stargardt's disease.

* These products are currently in development by Sirion Therapeutics and are not FDA approved.

Contact Information

Sirion Therapeutics – Corporate Headquarters
9314 East Broadway Avenue
Tampa, Florida 33619
Phone: (813) 496-7325
Fax: (813) 496-7328

Sirion Therapeutics – Research and Development Facility
11408 Sorrento Valley Road
San Diego, California 92121
Phone: (858) 875-9250
Fax: (858) 875-9251

www.siriontherapeutics.com

For more information regarding investor & media relations, please contact:

Ed Stevens
Chase Communications
(727) 327-3396
estevens@chasepr.com